Jan Philipp Bewersdorf, MD, FACP
he/him/his
Assistant ProfessorDownloadHi-Res Photo
Cards
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileContact Info
Hematology
333 Cedar Street, PO Box 208028
New Haven, CT 06520
United States
About
Titles
Assistant Professor
Biography
Dr. Jan Philipp Bewersdorf is an Assistant Professor of Medicine (Hematology) at Yale University. Following medical school training in Germany, he completed his Internal Medicine training at Yale - New Haven Hospital. After completion of residency, Dr. Bewersdorf pursued his fellowship in Hematology and Medical Oncology at Memorial Sloan Kettering Cancer Center in New York before joining the faculty at Yale in July 2024. Dr. Bewersdorf is board-certified in Internal Medicine, Medical Oncology and Hematology.
His career as a clinician-scientist has been dedicated to myeloid malignancies spanning from myeloproliferative neoplasms to myelodysplastic syndromes and acute myeloid leukemia. Dr. Bewersdorf's work aims to combine basic and translational research with clinical and outcomes research to study those disorders from multiple angles. Inspired by the privilege of taking care of patients with myeloid neoplasms, he strives to advance patient care by conducting innovative clinical trials with a strong correlative component in collaboration with laboratory-based colleagues. He has developed and co-led several early phase clinical trials in myeloid malignancies and his research efforts have led to over 130 peer-reviewed publications to date including first-author publications in Lancet, Blood, Leukemia, and Lancet Haematology.
Dr. Bewersdorf has received several prestigious awards including the Edwards P. Evans Young Investigator Award, the Mortimer Lacher Fellowship from the Lymphoma Foundation, and multiple other achievement awards. He also serves on the editorial board and is a reviewer of several important hematology and oncology journals.
Appointments
Education & Training
- Fellowship
- Memorial Sloan Kettering Cancer Center (2024)
- Chief Fellow
- Memorial Sloan Kettering Cancer Center (2024)
- Resident
- Yale - New Haven Hospital (2021)
- Resident
- Ludwig-Maximilians-University Munich (2018)
- MD
- Ludwig-Maximilians-University Munich (2017)
Research
Overview
Medical Research Interests
Clinical Trial; Immune System; Leukemia; Leukemia, Myeloid; Myelodysplastic Syndromes
Public Health Interests
Health Economics
ORCID
0000-0003-3352-0902
Research at a Glance
Yale Co-Authors
Frequent collaborators of Jan Philipp Bewersdorf's published research.
Publications Timeline
A big-picture view of Jan Philipp Bewersdorf's research output by year.
Research Interests
Research topics Jan Philipp Bewersdorf is interested in exploring.
Amer Zeidan, MBBS
Rory Shallis, MD
Nikolai Podoltsev, MD, PhD
Scott Huntington, MD, MPH, MSc
Stephanie Halene, MD, Dr Med
Rong Wang, PhD
200Publications
2,324Citations
Myelodysplastic Syndromes
Leukemia
Leukemia, Myeloid
Publications
2024
Acute Promyelocytic Leukemia in the Real World: Understanding Outcome Differences and How We Can Improve Them
Bidikian A, Bewersdorf J, Kewan T, Stahl M, Zeidan A. Acute Promyelocytic Leukemia in the Real World: Understanding Outcome Differences and How We Can Improve Them. Cancers 2024, 16: 4092. PMID: 39682277, PMCID: PMC11640703, DOI: 10.3390/cancers16234092.Peer-Reviewed Original ResearchConceptsAcute promyelocytic leukemiaAdvent of all-trans retinoic acidEarly mortalityLong-term treatment toxicitiesArsenic trioxidePromyelocytic leukemiaClinical practiceIncidence of acute promyelocytic leukemiaRates of remissionLong-term outcomesTreatment of acute promyelocytic leukemiaLong-term survivalComprehensive patient evaluationResource-limited settingsTreatment toxicityAll-trans retinoic acidDelayed diagnosisPatient demographicsSignificant comorbiditiesTreatment initiationOlder patientsExpert centersClinical trialsTreatment outcomesReal-world settingsCost-effectiveness of Enasidenib versus conventional care for older patients with IDH2-mutant refractory/relapsed AML
Alhajahjeh A, Patel K, Shallis R, Podoltsev N, Kewan T, Stempel J, Mendez L, Huntington S, Stahl M, Goshua G, Bewersdorf J, Zeidan A. Cost-effectiveness of Enasidenib versus conventional care for older patients with IDH2-mutant refractory/relapsed AML. Leukemia & Lymphoma 2024, ahead-of-print: 1-9. PMID: 39560957, DOI: 10.1080/10428194.2024.2426073.Peer-Reviewed Original ResearchAltmetricConceptsConventional care regimensOlder patientsTreatment of older patientsIDH2 inhibitor enasidenibIncremental cost-effectiveness ratioCost-effectiveness ratioProbabilistic sensitivity analysesR/R AMLRefractory/relapsed AMLEvent-freeCost-effective treatmentEnasidenibCare regimensAMLPatientsCost-effectiveIncremental costLife yearsConventional careR/RIncremental effectSurvivalTreatmentPhase Ib Study of PRT543, an Oral Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Patients with Relapsed or Refractory, Splicing Factor-Mutant Myeloid Malignancies
Bewersdorf J, Mi X, Lu B, Kuykendall A, Sallman D, Patel M, Stevens D, Philipovskiy A, Sutamtewagul G, Masarova L, Keiffer G, Verma A, Bhagwat N, Heiser D, Ro S, Hong W, Abdel-Wahab O, Stein E. Phase Ib Study of PRT543, an Oral Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Patients with Relapsed or Refractory, Splicing Factor-Mutant Myeloid Malignancies. Blood 2024, 144: 3215. DOI: 10.1182/blood-2024-198495.Peer-Reviewed Original ResearchConceptsTreatment-emergent adverse eventsPlatelet transfusion independenceProtein arginine methyltransferase 5Myeloid malignanciesSplicing factor mutationsSymmetric dimethyl arginineMedian PFSTransfusion independenceFollow-upOpen-label phase Ib studyRed blood cell transfusion-dependentPRMT5 inhibitionAdequate end-organ functionBaseline serum EPO levelsRecommended phase 2 doseMedian duration of treatmentGrade 5 eventsLower-risk MDSMDS/MPN overlap syndromesPhase 2 doseIntensive induction chemotherapyPeripheral blood mononuclear cellsHigh-risk MDSPhase Ib studyMedian follow-upMis-Splicing Derived Neoantigens and Cognate T Cell Receptors in Splicing Factor Mutant Myeloid Neoplasms
Kim W, Crosse E, De Neef E, Etxeberria I, Sabio E, Wang E, Bewersdorf J, Lu S, Belleville A, Fox N, Castro C, Zhang P, Fujino T, Lewis J, Rahman J, Zhang B, Winick J, Lewis A, Stanley R, Dewolf S, Meskauskaite Urben B, Takizawa M, Krause T, Molina H, Chaligne R, Koppikar P, Molldrem J, Gigoux M, Merghoub T, Daniyan A, Greenbaum B, Klebanoff C, Bradley R, Abdel-Wahab O. Mis-Splicing Derived Neoantigens and Cognate T Cell Receptors in Splicing Factor Mutant Myeloid Neoplasms. Blood 2024, 144: 343-343. DOI: 10.1182/blood-2024-198639.Peer-Reviewed Original ResearchConceptsCD8+ T cellsT cell receptorPrimary human T cellsHuman T cellsT cellsHLA-ILeukemic cellsSRSF2 mutationsHealthy donorsIsolated CD8+ T cellsGraft-versus-leukemia effectT cell cytotoxic functionTCR-T cell therapyVirus-reactive T cellsAllogeneic stem cell transplantationT cell-based immunotherapyT cell receptor clonotypesLyse leukemic cellsPatient PBMC samplesCognate T cell receptorsDonor T cellsHigh-risk MDSStem cell transplantationHLA class IMis-splicingClinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database
Getz T, Kewan T, Bewersdorf J, Stempel J, Lanino L, Wei W, Al Ali N, DeZern A, Sekeres M, Uy G, Carraway H, Desai P, Griffiths E, Stein E, Brunner A, McMahon C, Shallis R, Zeidner J, Savona M, Ball S, Chandhok N, Logothetis C, Bidikian A, Roboz G, Rolles B, Wang E, Harris A, Amaya M, Hawkins H, Grenet J, Xie Z, Madanat Y, Abaza Y, Badar T, Haferlach T, Maciejewski J, Sallman D, Enjeti A, Al-Rabi K, Halahleh K, Hiwase D, Diez-Campelo M, Valcarcel D, Haferlach C, Pleyer L, Kotsianidis I, Pappa V, Santini V, Consagra A, Al-Kali A, Ogawa S, Nannya Y, Stahl M, Della Porta M, Komrokji R, Zeidan A. Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database. Blood 2024, 144: 3219-3219. DOI: 10.1182/blood-2024-202075.Peer-Reviewed Original ResearchConceptsNon-complex karyotypeInternational Prognostic Scoring SystemCytogenetic risk groupHMA initiationComplex karyotypeIPSS-RHypomethylating agentsOverall survivalRisk groupsCytogenetic abnormalitiesAllogeneic hematopoietic stem cell transplantationHematopoietic stem cell transplantationAssociated with worse survivalHypomethylating agent combinationsPoor-risk cytogeneticsPeripheral blood blastsTreated with azacitidinePrognostic Scoring SystemMeasured overall survivalStem cell transplantationKaplan-Meier methodLog-rank testOutcomes of PTTime-to-event analysisRisk of patientsComparative Analysis of Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients Harboring Very-High Risk Cytogenetics
Aguirre L, Bewersdorf J, Liu Y, Shallis R, Boussi L, Zucenka A, Garciaz S, Bystrom R, DeAngelo D, Stone R, Luskin M, Garcia J, Winer E, Ling K, Chen E, Wadleigh M, Stein E, Goldberg A, Zeidan A, Shimony S, Stahl M. Comparative Analysis of Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients Harboring Very-High Risk Cytogenetics. Blood 2024, 144: 4267-4267. DOI: 10.1182/blood-2024-202744.Peer-Reviewed Original ResearchConceptsMorphologic leukemia-free stateComposite complete remissionTreated with ICIntensive chemotherapyMonosomal karyotypeComplex karyotypeProgressive diseaseSurvival outcomesTreatment strategiesAllogeneic hematopoietic stem cell transplantationComposite complete remission rateTreated with intensive chemotherapyHematopoietic stem cell transplantationComparative analysis of outcomesDismal survival outcomesConventional cytotoxic chemotherapyAggressive disease biologyMulticenter retrospective cohortStem cell transplantationAnalyze survival outcomesKaplan-Meier methodLog-rank testAnalysis of outcomesCK-AMLCPX-351Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients with Chromosome 5 and 7 Abnormalities
Boussi L, Bewersdorf J, Liu Y, Shallis R, Aguirre L, Zucenka A, Garciaz S, Bystrom R, DeAngelo D, Stone R, Luskin M, Garcia J, Winer E, Chen E, Wadleigh M, Ling K, Zeidan A, Goldberg A, Stein E, Shimony S, Stahl M. Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients with Chromosome 5 and 7 Abnormalities. Blood 2024, 144: 4281-4281. DOI: 10.1182/blood-2024-204467.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaMedian OSTP53 co-mutationsTreated with ICIntensive chemotherapyComposite CRCo-mutationsComplete remissionOverall survivalPts ageAllogeneic stem cell transplantationSecondary acute myeloid leukemiaDiagnosed AMLAcute myeloid leukemia patientsAssociated with poor outcomesEstimate overall survivalStem cell transplantationKaplan-Meier methodLog-rank testPredictors of survivalCPX-351Monosomy 5MRD negativityInduction therapyComplex karyotypeArtificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features
Lanino L, D'Amico S, Maggioni G, Al Ali N, Wang Y, Gurnari C, Gagelmann N, Bewersdorf J, Ball S, Guglielmelli P, Meggendorfer M, Hunter A, Kubasch A, Travaglino E, Campagna A, Ubezio M, Russo A, Todisco G, Tentori C, Buizza A, Sauta E, Zampini M, Riva E, Asti G, Delleani M, Ficara F, Santoro A, Sala C, Dall'Olio D, Dall'Olio L, Kewan T, Casetti I, Awada H, Xicoy B, Vucinic V, Hou H, Chou W, Yao C, Lin C, Tien H, Consagra A, Sallman D, Kern W, Bernardi M, Chiusolo P, Borin L, Voso M, Pleyer L, Palomo L, Quintela D, Jerez A, Cornejo E, Martin P, Díaz-Beyá M, Pita A, Roldan V, Suarez D, Velasco E, Calabuig M, Garcia-Manero G, Loghavi S, Platzbecker U, Sole F, Diez-Campelo M, Maciejewski J, Kröger N, Fenaux P, Fontenay M, Santini V, Haferlach T, Germing U, Padron E, Robin M, Passamonti F, Solary E, Vannucchi A, Castellani G, Zeidan A, Komrokji R, Della Porta M. Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features. Blood 2024, 144: 1005. DOI: 10.1182/blood-2024-204826.Peer-Reviewed Original ResearchConceptsGenomic featuresSplicing mutationBiallelic inactivationAnalysis of genomic profilesBiallelic inactivation of TP53Clinical phenotypeGene expression profilesCNV analysisMorphological featuresInactivation of TP53Myeloid neoplasmsGenomic characterizationRNAseq dataMorphological dataMutation screeningExpression profilesMutationsJAK/STATGenomic profilingGenomeHierarchical importanceHeterogeneous phenotypesIntegrated analysisPhenotypeHematological phenotypeThe Prognostic and Predictive Value of RUNX1 Mutations in Newly Diagnosed Acute Myeloid Leukemia - an International Multicenter Cohort Study
Bystrom R, Bewersdorf J, Liu Y, Schaefer E, Shallis R, Boussi L, Zucenka A, Garciaz S, Aguirre L, DeAngelo D, Stone R, Luskin M, Garcia J, Winer E, Chen E, Wadleigh M, Ling K, Stein E, Goldberg A, Zeidan A, Shimony S, Stahl M. The Prognostic and Predictive Value of RUNX1 Mutations in Newly Diagnosed Acute Myeloid Leukemia - an International Multicenter Cohort Study. Blood 2024, 144: 2947-2947. DOI: 10.1182/blood-2024-205581.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaComposite complete responseMedian OSRUNX1 mutationsComplete responseIntensive chemotherapyOverall survivalMyelodysplastic syndromeAllo-SCTIntermediate riskPredictive valueMyeloid leukemiaInternational multicenter retrospective cohort studyTreatment strategiesCohort studyNewly diagnosed acute myeloid leukemiaAllogeneic stem cell transplantationMulticenter retrospective cohort studyNext-generation sequencingAntecedent MDSConcomitant TP53 mutationIncomplete count recoveryTreated with ICStem cell transplantationAdverse risk featuresLeukemia Physician's Perspective on Transplant in Patients with TP53 Mutated Acute Myeloid Leukemia
Moreno Vanegas Y, El Khatib S, Hisrich B, Coltoff A, Shallis R, Patel A, Bewersdorf J, Oh T, Abaza Y, Foucar C, Goldberg A, Duvall A, Atallah E, Litzow M, Badar T. Leukemia Physician's Perspective on Transplant in Patients with TP53 Mutated Acute Myeloid Leukemia. Blood 2024, 144: 1487-1487. DOI: 10.1182/blood-2024-205782.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaTP53-mAllo-HCTComplex cytogeneticsHypomethylating agentsInternational Consensus ClassificationRefractory diseaseSecondary AMLOverall survivalMyeloid leukemiaTP53-mutated acute myeloid leukemiaDe novo acute myeloid leukemiaProgressive acute myeloid leukemiaSecondary acute myeloid leukemiaAllogeneic hematopoietic cell transplantationMedian overall survivalTP53 allelic stateIncomplete count recoveryLow-intensity regimensReviewed electronic medical recordsHematopoietic cell transplantationRate of relapseMulticenter observational studyOverall response ratePatient selection criteria
Clinical Trials
Current Trials
A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults With Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Treatment Trial
HIC ID2000036670RolePrincipal InvestigatorPrimary Completion Date10/31/2025Recruiting ParticipantsMYELOMATCH: A Screening Study to Assign People with Myeloid Cancer to a Treatment Study or Standard of Care Treatment within myeloMATCH (MyeloMATCH Screening Trial)
HIC ID2000036669RolePrincipal InvestigatorPrimary Completion Date05/15/2029Recruiting ParticipantsA Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Study of AK117/Placebo in Combination With Azacitidine in Patients With Newly Diagnosed Higher-risk Myelodysplastic Syndromes
HIC ID2000036615RoleSub InvestigatorPrimary Completion Date01/31/2026Recruiting ParticipantsVenetoclax in Combination with ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndromes/Myeloproliferative Neoplasms
HIC ID2000035366RolePrincipal InvestigatorPrimary Completion Date08/31/2025Recruiting ParticipantsA Randomized Phase II Study Comparing Inotuzumab Plus Chemotherapy Versus Standard Chemotherapy in Older Adults With Philadelphia-Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
HIC ID2000034665RoleSub InvestigatorPrimary Completion Date05/31/2028Recruiting Participants
Academic Achievements & Community Involvement
activity Expert Reviews of Hematology
Journal ServiceReviewerDetails2019 - Presentactivity Cancer
Journal ServiceReviewerDetails2020 - Presentactivity Leukemia
Journal ServiceReviewerDetails2021 - Presentactivity Clinical Cancer Research
Journal ServiceReviewerDetails2022 - Presentactivity Blood Advances
Journal ServiceReviewerDetails2024 - Present
Clinical Care
Overview
Clinical Specialties
Hematology; Hematologic Oncology; Leukemia & Lymphoma
Fact Sheets
Diagnosing Leukemia
Learn More on Yale MedicineCytogenic Studies for Leukemia Diagnosis
Learn More on Yale MedicineLeukemia in Children
Learn More on Yale Medicine
Board Certifications
Hematology (Internal Medicine)
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2024
Medical Oncology
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2023
Internal Medicine
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2021
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews
News
- August 14, 2024
Welcome New Staff, Faculty, Fellows, Postgrads & Postdocs (August 2024)
- July 17, 2024
Hematologist, Dr. Jan Bewersdorf, Joins Smilow Cancer Hospital
- March 10, 2021
Discoveries & Impact (March 2021)
- October 14, 2020
Discoveries & Impact (October 2020)
Get In Touch
Contacts
Appointment Number
Mailing Address
Hematology
333 Cedar Street, PO Box 208028
New Haven, CT 06520
United States
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.